Press review
The essentials of recent medical publications, unpacked by our newsroom into a clear, sourced digest, specialty by specialty.
NephrologyaHUS: Towards More Effective and Better-Adapted Treatments?
#RareDisease #aHUS #Nephrology #KidneyFailure Atypical hemolytic uremic syndrome (aHUS) is a rare and severe disease classified under thrombotic microangiopathies (TMA). It results from uncontrolled activation of the alternative complement pathway, leading to endothelial damage, microthrombi formation, and capillary obstruction. This pathological cascade causes non-immune hemolytic anemia, thrombo
Gastroenterology and HepatologyMicroRNAs & Microbiota: An Inflammatory Duo?
#MicroRNA #Microbiota #IBD #Immunotherapy #Innovation Chronic inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, are characterized by persistent inflammation of the digestive tract, associated with an imbalance in the gut microbiota. This dysbiosis, combined with an exacerbated immune response, contributes to the chronicity of symptoms and complicates patient manage
InfectiologyVaccine-derived poliovirus: a threat under surveillance
#Poliovirus #InfectiousDiseases #Vaccine #Vaccination #nOPVS2 #Immunity #cVDPV Circulating vaccine-derived polioviruses (cVDPVs) remain a persistent threat to public health, particularly in regions where vaccination coverage is insufficient. These viruses emerge when the attenuated strain of the oral polio vaccine (OPV) undergoes mutations after prolonged circulation within under-immunized populat
InfectiologyHBsAg and immunity: a barrier or an ally against hepatitis B?
#InfectiousDiseases #Hepatitis #HepatitisB #Immunity #Immunotherapy #Virus Chronic hepatitis B (HBV) is a persistent viral infection affecting more than 300 million people worldwide. Despite therapeutic advancements, achieving functional cure remains a challenging goal, as current treatments only control viral replication without completely eradicating the infection. One of the main obstacles to t
NeurologyLITT vs. Surgery: The Revolution in Temporal Epilepsy Treatments?
#Epilepsy #Surgery #LITT #Neurology #Neurosurgery Mesial temporal lobe epilepsy (mTLE) is the most common form of drug-resistant focal epilepsy, affecting approximately one-third of epilepsy patients. This condition is characterized by recurrent seizures that do not respond to standard antiepileptic treatments, significantly impacting patients' quality of life. The standard treatment for drug-resi
Cardiology and Vascular MedicineGenes and the Heart: The Hidden Link of MTHFD1-G1958A
#Cardiology #CongenitalHeartDisease #GeneEnvironmentInteraction #MTHFD1 Congenital heart diseases (CHD) are among the most common birth defects, affecting approximately 1 to 1.2% of newborns. Their origin is multifactorial, resulting from a complex interaction between genetic predispositions and environmental factors. Among the genes involved, MTHFD1 plays a central role in folate metabolism and t
NeurologyPredicting Amyloid: AI for Early Detection
#Alzheimer’s #MachineLearning #Neurology #Screening #AmyloidPlaque The accumulation of amyloid plaques in the brain is a key pathological feature of Alzheimer’s disease. These plaques often appear years, even decades, before cognitive symptoms emerge. Their accumulation is associated with an increased risk of cognitive decline, making them a priority target for screening and early intervention. Ho
OncologyOncology: When AI Takes Control…
#Oncology #ArtificialIntelligence #Cancer #NewTherapy The integration of artificial intelligence (AI) in oncology marks a revolution in the management of cancer patients. Thanks to its advanced analytical capabilities, AI efficiently processes narrative data, which constitute more than 80% of the information contained in electronic medical records. These data, often difficult to exploit manually,
OncologyRadium-223 & Enzalutamide: A Powerful Duo Against mCRPC!
#Oncology #ProstateCancer #mCRPC #Radium223 #Enzalutamide #CombinationTherapy #Immunotherapy #NuclearMedicine Castration-resistant prostate cancer (mCRPC) is one of the most advanced and aggressive stages of the disease. Tumors become insensitive to androgen deprivation and continue to grow despite low testosterone levels. Bone metastases, a hallmark of mCRPC, cause severe complications that impac
OncologyNIAGARA: A Wave of Hope for Invasive Bladder Cancer
#Oncology #MIBC #Immunotherapy #Chemotherapy #NIAGARA #CombinationTherapy #PersonalizedMedicine Muscle-invasive bladder cancer (MIBC) is an aggressive form of urothelial carcinoma characterized by invasion into the bladder muscle layer. Associated with a high risk of metastatic progression and recurrence, this condition has a low five-year survival rate, particularly when diagnosed at an advanced
OncologyTIGIT: Brake or Springboard Against Cancer?
#Oncology #Immunotherapy #TIGIT #Cancer #TherapeuticCombination #NKCell #TLymphocyte #PredictiveBiomarker Immunotherapy has revolutionized cancer treatment by leveraging the immune system to fight tumor cells. However, despite its successes, it often faces resistance that limits its effectiveness, particularly in advanced cancers. Among the mechanisms of tumor immune evasion, the role of TIGIT (T-
OncologyPSMA, a revolution against prostate cancer
#ProstateCancer #Cancer #Prostate #Therapy #Innovation #PSMATargetedTherapy #Immunotherapy Prostate cancer is one of the most common cancers in men and remains a leading cause of cancer-related mortality worldwide. With increasing life expectancy and improved screening techniques, its incidence continues to rise. While conventional treatments—hormone therapy, chemotherapy, and radiotherapy—can con